Vyome Q1 2025 net loss widens to $294K; going concern raises risk for ReShape merger

Vyome Holdings, Inc

Vyome revenue rose to $198.6K (Q1 2025) from $77.0K YoY, but net loss widened from $127K to $294K.
Current liabilities exceed current assets by $5.2M; substantial doubt about Vyome's going concern is disclosed.
Convertible debt current portion stands at $3.84M; company relies on continued note issuances for funding.
Pro forma combined financials filed as part of ReShape's S-3 shelf registration for the pending merger.
Vyome plans FDA meeting for VT-1953 pivotal trial in Q3 2025; has Phase III-ready acne program.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.